| Document |
Document Title |
|
WO/2024/030627A1 |
Provided herein are compounds having a structure of formula (A), or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rd, and n are described herein. Also provided herein are compositions comprising compounds of Formula ...
|
|
WO/2024/029992A1 |
The present invention relates to a peptide capable of directly binding to amyloid beta protein Aβ42, which is known to be a causative agent of Alzheimer's disease, and a composition for the treatment and prevention of Alzheimer's diseas...
|
|
WO/2024/031053A1 |
Provided herein are TDP-43 variants in which a prion-like domain (PLD) of the TDP-43 variant is mutated to have more aromatic amino acids and/or aromatic amino acids that are more evenly spaced than in a PLD from a wild type TDP-43, nucl...
|
|
WO/2024/029242A1 |
Disclosed is a linear peptide or cyclic peptide having an amino acid sequence represented by formula (1): XN-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15 (1), or a pharmacologically acceptable salt thereof. Binding this peptide to LRP1 makes i...
|
|
WO/2024/028483A1 |
The present invention relates to brain derived nerve factor (BDNF) for use in the prevention or treatment of sensorineural hearing loss in a subject, wherein said BDNF is administered intranasally to said subject.
|
|
WO/2024/028779A1 |
Provided herein are vaporizer formulations comprising fungal material from Amanita muscaria and/or an extract thereof, as well as devices comprising the same. Also provided are methods of using the disclosed formulations and devices to m...
|
|
WO/2024/030628A1 |
The present invention provides deuterium-enriched compounds, compositions thereof, and methods of using the same.
|
|
WO/2024/026573A1 |
The present application relates to 3-ethylamino-indole dimers of general Formula I, to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treat...
|
|
WO/2024/028349A2 |
The present invention relates to levodopa for preventing the development of addiction and/or dependence to prescribed stimulants in a subject treated with stimulants. The present invention also relates to the use of a composition, pharma...
|
|
WO/2024/028495A1 |
The present invention relates generally to substituted ergoline compounds and compositions, more particularly new lysergamide derivatives and compositions, and applications of these. The invention furthermore relates to a new production ...
|
|
WO/2024/028487A1 |
The present invention relates to nerve growth factor (NGF) or a mutein thereof for use in the prevention or treatment of sensorineural hearing loss in a subject, wherein said NGF is administered intranasally to said subject.
|
|
WO/2024/030504A1 |
The invention provides methods of treating patients with Parkinson's disease (PD) associated with wild-type LRRK2. The invention recognizes that analysis of biomarkers in such patients allows identification of those patients who will res...
|
|
WO/2024/026568A1 |
Disclosed are novel fused heterocyclic mescaline derivative compounds, notably fused heterocyclic mescaline derivatives and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compound...
|
|
WO/2024/028808A1 |
The present disclosure relates to compounds of Formula (I) which modulate the activity of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, au...
|
|
WO/2024/027723A1 |
Disclosed in the present invention are a crystal form, a salt type and a composition of a pyridazine compound and a preparation method therefor, and specifically disclosed are a method for preparing a crystal form A and a composition of ...
|
|
WO/2024/029638A1 |
The present invention relates to a series of novel heterocyclyl-phenyl-methylamine derivatives, a preparation method therefor, and a use thereof for prevention, alleviation, or treatment of multiple sclerosis.
|
|
WO/2024/028731A1 |
Provided are novel multispecific antibodies comprising at least one of a first antigen-binding region and a second antigen-binding region each capable of binding specifically to human epidermal growth factor receptor 2 (HER2), and a thir...
|
|
WO/2024/029678A1 |
The present invention relates to a use of PDH inhibitors in the treatment of neurodegenerative diseases, and according to the present invention, in a DJ-1 deletion Parkinson's disease Drosophila model, by activation of PDK, promotion of ...
|
|
WO/2024/029535A1 |
The present invention provides a polypeptide that specifically recognizes a structurally abnormal protein caused by misfolding, etc. in mammals, and a detection agent and a reduction agent for a structurally abnormal protein with the use...
|
|
WO/2024/027752A1 |
Provided are a pharmaceutical composition comprising a heterocyclic compound, a preparation method therefor, and use thereof. Further provided is a pharmaceutical composition Q, comprising a substance X and a pharmaceutical excipient, th...
|
|
WO/2024/027751A1 |
Disclosed are a crystal form of a heterocyclic compound, a preparation method therefor, and the use thereof. The heterocyclic compound is the compound represented by formula I. For the crystal form thereof, the X-ray powder diffraction p...
|
|
WO/2024/030560A2 |
Power equipment includes a chassis, an implement coupled to the chassis, and a battery system coupled to the chassis. The battery system includes a first battery pack, a second battery pack, a circuit including a first switch configured ...
|
|
WO/2024/029995A1 |
The present invention relates to a peptide capable of directly binding to amyloid beta protein Aβ42, known to be a causative agent of Alzheimer's disease, and a composition for treating and preventing Alzheimer's disease, comprising the...
|
|
WO/2024/028516A1 |
A synthesis method for the preparation of a cannabinoid selected from cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), comprising the steps of: a) dissolving olivetol in dichloromethane (DCM) with stirring; b) adding FeCl3 * 6H2O as...
|
|
WO/2024/028611A1 |
The present invention provides for an effective pharmacological therapy for obsessive compulsive disorder.
|
|
WO/2024/029962A1 |
The present invention relates to use of a novel PPAR activity modulator for the prevention, amelioration or treatment of degenerative brain diseases and, more specifically, provides a composition for the prevention, amelioration or treat...
|
|
WO/2024/029630A1 |
The present disclosure provides a cyclic peptide derivative, a method for producing the same, and a composition. The present disclosure pertains to a compound for neural cell activity regulation. More specifically, the compound of the pr...
|
|
WO/2024/028732A1 |
Provided are novel multispecific antibodies comprising at least one of a first antigen-binding region and a second antigen-binding region each capable of binding specifically to human epidermal growth factor receptor 2 (HER2), and a thir...
|
|
WO/2024/027800A1 |
The present invention relates to a new compound as a 5-HT2A receptor inverse agonist, a preparation method therefor and a pharmaceutical composition. The present invention further relates to the use of the compound or the pharmaceutical ...
|
|
WO/2024/027116A1 |
Provided are compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4, Q, n, and A are described herein, which are useful as Lp-PLA2 inhibitors, pharmaceutical compositions comprising the ...
|
|
WO/2024/028458A2 |
This invention relates to compounds and salts thereof that are muscarinic receptor agonists and which are useful in the treatment of muscarinic receptor mediated diseases. Also provided are crystalline forms of the compounds and salts th...
|
|
WO/2024/027845A1 |
Provided is the following compound (I) or a pharmaceutically acceptable salt, ester, optical isomer, stereoisomer, polymorph, solvate, N-oxide, isotopically-labeled compound, metabolite, chelate, complex, inclusion complex, or prodrug th...
|
|
WO/2024/031030A2 |
A method of treatment of mental disorder of a subject includes the steps of: normalizing an expression of both DRD1 and DRD5, which belong to DRDl-like family, of the subject to a preset standard level. The DRD1/5 level and expression ca...
|
|
WO/2024/029620A1 |
The present invention relates to a cerebral blood flow augmenter that contains isomaltulose as an active ingredient.
|
|
WO/2024/029599A1 |
Provided is a pharmaceutical composition containing, as an active ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methox
yphenyl)pyrrolidine-3-yl]carbonyl}-4-(methoxymethyl)pyrrolid
ine-3-yl]-5-(trifluoromethyl)phenyl}p...
|
|
WO/2024/025042A1 |
A composition comprising AAV2-ANKS1A recombinant virus for treating Alzheimer's disease is provided. Specifically, it is identified that ANKS1A (ankyrin repeat and sterile alpha motif domain containing 1A) protein binds to an LRP1 recept...
|
|
WO/2023/010078A9 |
The present invention relates to compounds of Formula (Ia), pharmaceutically acceptable salts of compounds of Formula (Ia), and pharmaceutical compositions thereof that modulate the activity of the muscarinic acetylcholine receptor M4. C...
|
|
WO/2024/026350A1 |
Compounds having opioid characteristics are provided that can be used for various therapeutic methods including the treatment of pain and opioid use disorders, and compounds having opioid antagonist properties that can be used to treat o...
|
|
WO/2024/022528A1 |
Disclosed are compounds having general formula I, a method for preparing same, a pharmaceutical composition thereof, and use thereof. Specifically, the present invention provides a compound having a structure represented by general formu...
|
|
WO/2024/024985A1 |
Provided is a drug for treating Alzheimer's disease, the drug enabling retention of cognitive function amelioration and nerve quality improvement for a specific time even after treatment ends. This drug for causal treatment of Alzheime...
|
|
WO/2024/023128A1 |
The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2024/021626A1 |
Disclosed in the present invention are pramipexole xinafoate and a sustained-release pharmaceutical preparation thereof. In the present invention, after pramipexole is prepared into pramipexole xinafoate, the solubility of salts of prami...
|
|
WO/2024/023281A1 |
The invention concerns a novel and innovative composition for the treatment of neuropathic pain (NP). Specifically, the invention concerns HfO2 nanoparticles and/or aggregates of HfO2 nanoparticles, a composition comprising said nanopart...
|
|
WO/2024/020953A1 |
Provided are a steroid compound for treating a central nervous system disease, a method for preparing same, and use and a pharmaceutical composition thereof. The steroid compound has a 9β,10α structure and has the following structural ...
|
|
WO/2024/023287A1 |
The present invention relates to a compound of general formula (I). The invention further relates to the compounds of the invention as neuroprotective and/or neurorestorative agents, in particular for use in the treatment of neurological...
|
|
WO/2024/026306A1 |
The present invention provides methods for targeting an agent to the peripheral nervous system of a subject. In these methods, targeting is achieved by conjugating the agent to an antibody that can transport conjugated cargo across the b...
|
|
WO/2024/026337A1 |
This invention relates to crystalline solvated forms of Compound (1) and pharmaceutical compositions thereof. Also disclosed herein are methods of making crystalline solvated solid forms of Compound (1), and methods of using the crystall...
|
|
WO/2024/024961A1 |
The present invention relates to a therapeutic agent and/or prophylactic agent for central nervous system diseases involving abnormal aggregates of brain proteins. The therapeutic agent and/or prophylactic agent contains, as active ingre...
|
|
WO/2024/024565A1 |
The present invention addresses the problem of providing an agent that suppresses cell aging and a drug that prevents or treats diseases and the like caused by cell aging. More specifically, the present invention is a cell aging suppress...
|
|
WO/2024/026420A1 |
Systems and methods for the identification of auto-antibodies associated with central nervous system or psychiatric disease or disorders. Also disclosed herein are methods of treating central nervous system or psychiatric disease or diso...
|
